  Objective To assess the price elasticity of branded imatinib in chronic
myeloid leukemia (CML) patients on Medicare Part D to determine if high
out-of-pocket payments (OOP) are driving the substantial levels of
non-adherence observed in this population.
  Data sources and study setting We use data from the TriNetX Diamond Network
(TDN) United States database for the period from first availability in 2011
through the end of patent exclusivity following the introduction of generic
imatinib in early 2016.
  Study design We implement a fuzzy regression discontinuity design to
separately estimate the effect of Medicare Part D enrollment at age 65 on
adherence and OOP in newly-diagnosed CML patients initiating branded imatinib.
The corresponding price elasticity of demand (PED) is estimated and results are
assessed across a variety of specifications and robustness checks.
  Data collection/extraction methods Data from eligible patients following the
application of inclusion and exclusion criteria were analyzed.
  Principal findings Our analysis suggests that there is a significant increase
in initial OOP of $232 (95% Confidence interval (CI): $102 to $362) for
individuals that enrolled in Part D due to expanded eligibility at age 65. The
relatively smaller and non-significant decrease in adherence of only 6
percentage points (95% CI: -0.21 to 0.08) led to a PED of -0.02 (95% CI:
-0.056, 0.015).
  Conclusion This study provides evidence regarding the financial impact of
coinsurance-based benefit designs on Medicare-age patients with CML initiating
branded imatinib. Results indicate that factors besides high OOP are driving
the substantial non-adherence observed in this population and add to the
growing literature on PED for specialty drugs.
